Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 4
2007 1
2009 1
2010 2
2011 2
2012 3
2013 4
2014 4
2015 1
2016 2
2017 2
2019 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Echizen H. Echizen H. Clin Pharmacokinet. 2016 Apr;55(4):409-18. doi: 10.1007/s40262-015-0326-7. Clin Pharmacokinet. 2016. PMID: 26369775 Review.
Vonoprazan is administered orally at 20 mg once daily for the treatment of gastroduodenal ulcer, at 20 and 10 mg once daily for the treatment and secondary prevention of reflux esophagitis, respectively, at 10 mg once daily for the secondary prevention of low-dose aspirin- …
Vonoprazan is administered orally at 20 mg once daily for the treatment of gastroduodenal ulcer, at 20 and 10 mg once daily for the treatmen …
Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial.
Hawkey C, Avery A, Coupland CAC, Crooks C, Dumbleton J, Hobbs FDR, Kendrick D, Moore M, Morris C, Rubin G, Smith M, Stevenson D; HEAT Trialists. Hawkey C, et al. Lancet. 2022 Nov 5;400(10363):1597-1606. doi: 10.1016/S0140-6736(22)01843-8. Lancet. 2022. PMID: 36335970 Free article. Clinical Trial.
BACKGROUND: Peptic ulcers in patients receiving aspirin are associated with Helicobacter pylori infection. We aimed to investigate whether H pylori eradication would protect against aspirin-associated ulcer bleeding. ...Participants were randomly assigned (1:1) to r …
BACKGROUND: Peptic ulcers in patients receiving aspirin are associated with Helicobacter pylori infection. We aimed to investigate wh …
Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
Pelliccia F, Rollini F, Marazzi G, Greco C, Gaudio C, Angiolillo DJ. Pelliccia F, et al. Eur J Pharmacol. 2015 Oct 15;765:332-6. doi: 10.1016/j.ejphar.2015.08.059. Epub 2015 Sep 2. Eur J Pharmacol. 2015. PMID: 26341013 Review.
The combination of aspirin and the thienopyridine clopidogrel is a cornerstone in the prevention of atherothrombotic events. ...Accordingly, the aim of this review is to highlight and discuss recent data on drug-drug interactions between clopidogrel an …
The combination of aspirin and the thienopyridine clopidogrel is a cornerstone in the prevention of atherothrombotic events. . …
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL, Cryer B, Amer F, Hunt B. Goldstein JL, et al. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1167-74. doi: 10.1016/j.cgh.2007.06.009. Clin Gastroenterol Hepatol. 2007. PMID: 17916545 Clinical Trial.
This study compared the incidence of gastroduodenal ulcers in patients treated with low-dose aspirin and a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug or a nonselective nonsteroidal anti-inflammatory drug plus the proton pump inhibitor l …
This study compared the incidence of gastroduodenal ulcers in patients treated with low-dose aspirin and a cyclooxygenase-2 selective …
East Asian perspective on the interaction between proton pump inhibitors and clopidogrel.
Zou D, Goh KL. Zou D, et al. J Gastroenterol Hepatol. 2017 Jun;32(6):1152-1159. doi: 10.1111/jgh.13712. J Gastroenterol Hepatol. 2017. PMID: 28024166 Review.
They are also co-prescribed with oral anticoagulant agents and with dual-antiplatelet therapy for the treatment and prevention of gastrointestinal bleeding. Clopidogrel belongs to the drug class of thienopyridines and is currently the most widely prescribed oral anticoagul …
They are also co-prescribed with oral anticoagulant agents and with dual-antiplatelet therapy for the treatment and prevention of gastrointe …
Proton pump inhibitors and clopidogrel: an association to avoid?
D'Ugo E, Rossi S, De Caterina R. D'Ugo E, et al. Intern Emerg Med. 2014 Feb;9(1):11-22. doi: 10.1007/s11739-013-1000-4. Epub 2013 Sep 13. Intern Emerg Med. 2014. PMID: 24030523 Review.
Dual antiplatelet therapy with aspirin and clopidogrel reduces cardiovascular events following an acute coronary syndrome or stent implantation, but the associated increased risk of gastro-intestinal bleeding often leads to the co-administration of proton pump inhibitors ( …
Dual antiplatelet therapy with aspirin and clopidogrel reduces cardiovascular events following an acute coronary syndrome or stent im …
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.
De Jaeghere EA, Tuyaerts S, Van Nuffel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Denys HG. De Jaeghere EA, et al. Cancer Immunol Immunother. 2023 Feb;72(2):475-491. doi: 10.1007/s00262-022-03253-x. Epub 2022 Aug 12. Cancer Immunol Immunother. 2023. PMID: 35960332 Free PMC article. Clinical Trial.
A phase II study (PRIMMO) of patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer is presented. Patients received an immunomodulatory five-drug cocktail (IDC) consisting of low-dose cyclophosphamide, aspirin, lansoprazole, v …
A phase II study (PRIMMO) of patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer is presented. Patients …
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Spiegel BM, Chiou CF, Ofman JJ. Spiegel BM, et al. Arthritis Rheum. 2005 Apr 15;53(2):185-97. doi: 10.1002/art.21065. Arthritis Rheum. 2005. PMID: 15818647 Free article. Review.
OBJECTIVE: To appraise the cost-effectiveness of competing therapeutic strategies in patient cohorts eligible for aspirin prophylaxis with varying degrees of gastrointestinal (GI) and cardiovascular risk. ...However, the addition of a PPI to a nonselective NSAID may be the …
OBJECTIVE: To appraise the cost-effectiveness of competing therapeutic strategies in patient cohorts eligible for aspirin prophylaxis …
Dipyridamole bioavailability in subjects with reduced gastric acidity.
Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR, Eisert W. Derendorf H, et al. J Clin Pharmacol. 2005 Jul;45(7):845-50. doi: 10.1177/0091270005276738. J Clin Pharmacol. 2005. PMID: 15951475 Clinical Trial.
An extended-release (ER) formulation of DP that employs tartaric acid to improve bioavailability of DP in the presence of elevated gastric pH was developed as a combination antiplatelet product with immediate-release aspirin. This crossover-designed study examined t …
An extended-release (ER) formulation of DP that employs tartaric acid to improve bioavailability of DP in the presence of elevated gastric p …
27 results